Literature DB >> 21970364

Hypoxia-inducible factor-1 (HIF-1) promotes LDL and VLDL uptake through inducing VLDLR under hypoxia.

Guo-Min Shen1, Ying-Ze Zhao, Ming-Tai Chen, Feng-Lin Zhang, Xiao-Ling Liu, Yi Wang, Chang-Zheng Liu, Jia Yu, Jun-Wu Zhang.   

Abstract

Metabolism under hypoxia is significantly different from that under normoxia. It has been well elucidated that HIF-1 (hypoxia-inducible factor-1) plays a central role in regulating glucose metabolism under hypoxia; however, the role of HIF-1 in lipid metabolism has not yet been well addressed. In the present study we demonstrate that HIF-1 promotes LDL (low-density lipoprotein) and VLDL (very-LDL) uptake through regulation of VLDLR (VLDL receptor) gene expression under hypoxia. Increased VLDLR mRNA and protein levels were observed under hypoxic or DFO (deferoxamine mesylate salt) treatment in MCF7, HepG2 and HeLa cells. Using dual-luciferase reporter and ChIP (chromatin immunoprecipitation) assays we confirmed a functional HRE (hypoxia-response element) which is localized at +405 in exon 1 of the VLDLR gene. Knockdown of HIF1A (the α subunit of HIF-1) and VLDLR, but not HIF2A (the α subunit of HIF-2), attenuated hypoxia-induced lipid accumulation through affecting LDL and VLDL uptake. Additionally we also observed a correlation between HIF-1 activity and VLDLR expression in hepatocellular carcinoma specimens. The results of the present study suggest that HIF-1-mediated VLDLR induction influences intracellular lipid accumulation through regulating LDL and VLDL uptake under hypoxia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21970364     DOI: 10.1042/BJ20111377

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  26 in total

1.  Nuclear factor (erythroid-derived 2)-like 2 activation-induced hepatic very-low-density lipoprotein receptor overexpression in response to oxidative stress contributes to alcoholic liver disease in mice.

Authors:  Zhigang Wang; Xiaobing Dou; Songtao Li; Ximei Zhang; Xinguo Sun; Zhanxiang Zhou; Zhenyuan Song
Journal:  Hepatology       Date:  2014-02-25       Impact factor: 17.425

2.  A Screening Study of Potential Carcinogen Biomarkers After Surgical Treatment of Obesity.

Authors:  Luciana Teixeira de Siqueira; Marcela Silvestre Outtes Wanderley; Roberto Afonso da Silva; Adriana da Silva Andrade Pereira; José Luiz de Lima Filho; Álvaro Antônio Bandeira Ferraz
Journal:  Obes Surg       Date:  2018-08       Impact factor: 4.129

3.  Hepatitis C virus utilizes VLDLR as a novel entry pathway.

Authors:  Saneyuki Ujino; Hironori Nishitsuji; Takayuki Hishiki; Kazuo Sugiyama; Hiroshi Takaku; Kunitada Shimotohno
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-23       Impact factor: 11.205

Review 4.  Role of Nrf2 in chronic liver disease.

Authors:  Wei Tang; Yong-Fang Jiang; Murugavel Ponnusamy; Mamadou Diallo
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

5.  Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease.

Authors:  Volker H Haase
Journal:  Kidney Int Suppl (2011)       Date:  2021-03-18

6.  Inhibin-expressing clear cell neuroendocrine tumor of the ampulla: an unusual presentation of von Hippel-Lindau disease.

Authors:  Hasan Gucer; Eva Szentgyorgyi; Shereen Ezzat; Sylvia L Asa; Ozgur Mete
Journal:  Virchows Arch       Date:  2013-08-04       Impact factor: 4.064

7.  High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers.

Authors:  Katharina Grupp; Stella Sanader; Hüseyin Sirma; Ronald Simon; Christina Koop; Kristina Prien; Claudia Hube-Magg; Georg Salomon; Markus Graefen; Hans Heinzer; Sarah Minner; Jakob R Izbicki; Guido Sauter; Thorsten Schlomm; Maria Christina Tsourlakis
Journal:  Mol Oncol       Date:  2013-07-19       Impact factor: 6.603

Review 8.  Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.

Authors:  Neil S Sanghani; Volker H Haase
Journal:  Adv Chronic Kidney Dis       Date:  2019-07       Impact factor: 3.620

9.  Characterization of missense mutations in the signal peptide and propeptide of FIX in hemophilia B by a cell-based assay.

Authors:  Wenwen Gao; Yaqi Xu; Hongli Liu; Meng Gao; Qing Cao; Yiyi Wang; Longteng Cui; Rong Huang; Yan Shen; Sanqiang Li; Haiping Yang; Yixiang Chen; Chaokun Li; Haichuan Yu; Weikai Li; Guomin Shen
Journal:  Blood Adv       Date:  2020-08-11

10.  Construction of PR39 recombinant AAV under control of the HRE promoter and the effect of recombinant AAV on gene therapy of ischemic heart disease.

Authors:  Lijun Sun; Yuewen Hao; Xiaowei Nie; Xuexin Zhang; Guangxiao Yang; Quanying Wang
Journal:  Exp Ther Med       Date:  2012-08-20       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.